The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...

Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to ...

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...

Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the ...

THURSDAY, June 12, 2025 (HealthDay News) — A newly approved shot could soon help protect babies from respiratory syncytial ...

The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.

Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among ...